SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Tulinsky A. Molecular interactions of thrombin. Semin Thromb Hemost 1996; 22: 11724.
  • 2
    Weitz JI, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 1998; 97: 54452.
  • 3
    Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 38591.
  • 4
    Bates SM, Weitz JI. The mechanism of action of thrombin inhibitors. J Invasive Cardiol 2000; 12 (Suppl. F): 27F32.
  • 5
    Stringer KA, Lindenfeld J. Hirudins: antithrombin anticoagulants. Ann Pharmacother 1992; 26: 153540.
  • 6
    Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998; 97: 2516.
  • 7
    Alban S. Pharmacological strategies for inhibition of thrombin activity. Curr Pharm Des 2008; 14: 115275.
  • 8
    Nutescu EA, Wittkowsky AK. Direct thrombin inhibitors for anticoagulation. Ann Pharmacother 2004; 38: 99109.
  • 9
    Lee CJ, Badhwar G, Ansell JE. Oral IIa inhibitors. Hematol Oncol Clin North Am 2010; 24: 73953, ix.
  • 10
    Weitz JI, Hirsh J, Samama MM. New anticoagulant drugs: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126 (3 Suppl.): 265S86.
  • 11
    Rydel TJ, Ravichandran KG, Tulinsky A, Bode W, Huber R, Roitsch C, Fenton JW. The structure of a complex of recombinant hirudin and human alpha-thrombin. Science 1990; 249: 27780.
  • 12
    Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005; 353: 102840.
  • 13
    Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133 (6 Suppl.): 141S59S.
  • 14
    Nutescu EA, Shapiro NL, Chevalier A. New anticoagulant agents: direct thrombin inhibitors. Cardiol Clin 2008; 26: 16987, v-vi.
  • 15
    Greinacher A, Warkentin TE. The direct thrombin inhibitor hirudin. Thromb Haemost 2008; 99: 81929.
  • 16
    Hirsh J, O'Donnell M, Weitz JI. New anticoagulants. Blood 2005; 105: 45363.
  • 17
    Iprivask [Package Insert]. Hunt Valley, MD: Canyon Pharmaceuticals, Inc, 2010.
  • 18
    Eriksson BI, Ekman S, Lindbratt S, Baur M, Bach D, Torholm C, Kalebo P, Close P. Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg Am 1997; 79: 32633.
  • 19
    Eriksson BI, Wille-Jorgensen P, Kalebo P, Mouret P, Rosencher N, Bosch P, Baur M, Ekman S, Bach D, Lindbratt S, Close P. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997; 337: 132935.
  • 20
    Frame JN, Rice L, Bartholomew JR, Whelton A. Rationale and design of the PREVENT-HIT study: a randomized, open-label pilot study to compare desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis. Clin Ther 2010; 32: 62636.
  • 21
    Serruys PW, Herrman JP, Simon R, Rutsch W, Bode C, Laarman GJ, van Dijk R, van den Bos AA, Umans VA, Fox KA, Close P, and Deckers JW for the Helvetica Investigators. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. N Engl J Med 1995; 333: 75763.
  • 22
    The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335: 77582.
  • 23
    Nafziger AN, Bertino JS Jr. Desirudin dosing and monitoring in moderate renal impairment. J Clin Pharmacol 2010; 50: 61422.
  • 24
    Steinmetzer T, Sturzebecher J. [From fibrinogen and hirudin to synthetic anticoagulants. Rational design of thrombin inhibitors]. Pharm Unserer Zeit 2004; 33: 196205.
  • 25
    Reed MD, Bell D. Clinical pharmacology of bivalirudin. Pharmacotherapy 2002; 22 (6 Pt 2): 105S11S.
  • 26
    Robson R, White H, Aylward P, Frampton C. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender. Clin Pharmacol Ther 2002; 71: 4339.
  • 27
    Warkentin TE. Bivalent direct thrombin inhibitors: hirudin and bivalirudin. Best Pract Res Clin Haematol 2004; 17: 10525.
  • 28
    Chew DP, Bhatt DL, Kimball W, Henry TD, Berger P, McCullough PA, Feit F, Bittl JA, Lincoff AM. Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. Am J Cardiol 2003; 92: 91923.
  • 29
    Steffel J, Luscher TF. Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors. J Cardiovasc Med (Hagerstown) 2009; 10: 61623.
  • 30
    De Caterina R. The current role of anticoagulants in cardiovascular medicine. J Cardiovasc Med (Hagerstown) 2009; 10: 595604.
  • 31
    Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001; 142: 9529.
  • 32
    Angiomax [Package Insert]. Parsippany, NJ: The Medicines Company, 2005.
  • 33
    Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289: 85363.
  • 34
    White H. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001; 358: 185563.
  • 35
    Mahaffey KW, Lewis BE, Wildermann NM, Berkowitz SD, Oliverio RM, Turco MA, Shalev Y, Ver Lee P, Traverse JH, Rodriguez AR, Ohman EM, Harrington RA, Califf RM. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol 2003; 15: 6116.
  • 36
    Koster A, Dyke CM, Aldea G, Smedira NG, McCarthy HL 2nd, Aronson S, Hetzer R, Avery E, Spiess B, Lincoff AM. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg 2007; 83: 5727.
  • 37
    Clayton SB, Acsell JR, Crumbley AJ 3rd, Uber WE. Cardiopulmonary bypass with bivalirudin in type II heparin-induced thrombocytopenia. Ann Thorac Surg 2004; 78: 21679.
  • 38
    Keisu M, Andersson TB. Drug-induced liver injury in humans: the case of ximelagatran. Handb Exp Pharmacol 2010; 196: 40718.
  • 39
    Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36: 38699.
  • 40
    Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292303.
  • 41
    Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47: 28595.
  • 42
    Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009; 48: 122.
  • 43
    Stangier J, Stahle H, Rathgen K, Roth W, Shakeri-Nejad K. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol 2008; 48: 14119.
  • 44
    Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stahle H, Rathgen K, Svard R. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005; 45: 55563.
  • 45
    Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008; 47: 4759.
  • 46
    Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009; 15 (Suppl. 1): 9S16S.
  • 47
    Stangier J, Rathgen K, Stahle H, Reseski K, Kornicke T, Roth W. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs 2009; 9: 5968.
  • 48
    Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract 2010; 64: 95667.
  • 49
    Wittkowsky AK. New oral anticoagulants: a practical guide for clinicians. J Thromb Thrombolysis 2010; 29: 18291.
  • 50
    van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 111627.
  • 51
    Eriksson BI, Dahl OE, Ahnfelt L, Kalebo P, Stangier J, Nehmiz G, Hermansson K, Kohlbrenner V. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost 2004; 2: 157380.
  • 52
    Eriksson BI, Dahl OE, Buller HR, Hettiarachchi R, Rosencher N, Bravo ML, Ahnfelt L, Piovella F, Stangier J, Kalebo P, Reilly P. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005; 3: 10311.
  • 53
    Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 2009; 101: 7785.
  • 54
    Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kalebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Buller HR. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 217885.
  • 55
    Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Buller HR. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 94956.
  • 56
    Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JA. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24: 19.
  • 57
    Huo M, Eriksson B, Dahl O, Kurth A, Hantel S, Hermansson K, Schnee J, Friedman R. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE-NOVATE II randomized trial. In: 15th Congress of the European Hematology Association (EHA) (Abstract #0564). Barcelona, Spain; 2010.
  • 58
    Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 234252.
  • 59
    Ezekowitz MD, Reilly PA, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-Azad K, Pedersen KE, Lionetti DA, Stangier J, Wallentin L. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007; 100: 141926.
  • 60
    Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363: 18756.
  • 61
    Oldgren J. RE-DEEM: Dabigatran added to dual antiplatelet therapy resulted in acceptable bleeding rates post-MI. In: American Heart Association Scientific Sessions (abstract #165). Orlando, FL; 2009.
  • 62
    McKellar S, Abel S, Camp C, Ereth M, Schaff H. Dabigatran is effective for thromboprophylaxis of mechanical heart valves. In: American Association for Thoracic Surgery 90th Annual Meeting (abstract). Toronto, ON, Canada; 2010.
  • 63
    Maegdefessel L, Linde T, Krapiec F, Hamilton K, Steinseifer U, van Ryn J, Raaz U, Buerke M, Werdan K, Schlitt A. In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves. Thromb Res 2010; 126: e196200.
  • 64
    Olsson SB, Rasmussen LH, Tveit A, Jensen E, Wessman P, Panfilov S, Wahlander K. Safety and tolerability of an immediate-release formulation of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Thromb Haemost 2010; 103: 60412.